Document is current
Any future updates will be listed below
-
Authors
Conroy, Faith
Miller, Rachael https://orcid.org/0000-0002-4594-0640
Alterman, Julia F.
Hassler, Matthew R.
Echeverria, Dimas
Godinho, Bruno M. D. C. https://orcid.org/0000-0001-6192-3333
Knox, Emily G.
Sapp, Ellen
Sousa, Jaquelyn
Yamada, Ken
Mahmood, Farah
Boudi, Adel
Kegel-Gleason, Kimberly
DiFiglia, Marian
Aronin, Neil
Khvorova, Anastasia https://orcid.org/0000-0001-6928-8071
Pfister, Edith L. https://orcid.org/0000-0002-0345-7773
-
Funding
Funding for this research was provided by:
CHDI Foundation (A-6119, A-5038)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (U01 NS114098, U01 NS114098)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
- License Information
-
More Information
Article History
Received: 15 January 2021
Accepted: 31 August 2022
First Online: 3 October 2022
Competing interests
: The authors declare the following competing interests: F.C., E.L.P., J.F.A., K.Y., N.A., and A.K. are inventors on patent application #16/988,391 based on the results reported in this work; the applicant is the University of Massachusetts, the status of which is currently non-final rejection. The basis of this application is contained in Figs. –. N.A. and E.P. are inventors on patent #20120136039 assigned to the University of Massachusetts upon which Fig. is based and A.K. and J.A. are inventors on patent #20200087663, assigned to the University of Massachusetts, upon which the chemical modifications patterns used in this study are based. A.K. and N.A. are co-founders and own stock in Atalanta Therapeutics. M.R.H. and B.M.D.C.G. are now employees of Atalanta Therapeutics. All other authors declare no competing interests.
